QUESTIONS UNDER INVESTIGATION
Clinical trial registrations.
A registry describes a study plan. It does not establish efficacy, confirm current availability or replace contact with the trial team. Check the original registry for the latest information.
Snapshot checked on 1 October 2026. Some records have not been updated for several years; recruitment labels below refer to the registry, not independently confirmed live status.
PRaG · SFRTNCT07342322
A Prospective, Multicenter, Open-label, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of Spatially Fractionated Radiotherapy Combined With the PraG Strategy for the Treatment of Soft Tissue Sarcoma
A Guangxi-sponsored study of spatially fractionated radiotherapy and a PRaG-based strategy for soft tissue sarcoma.
Not yet recruiting (registry record)
First posted: Jan 15, 2026 · Registry last updated: Jan 15, 2026Sponsor (as listed): First Affiliated Hospital of Guangxi Medical UniversityPRaG + cetuximab βNCT07327411
Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors
Investigates cetuximab beta with PRaG in EGFR-positive refractory solid tumors.
Not yet recruiting (registry record)
First posted: Jan 8, 2026 · Registry last updated: Jan 8, 2026Sponsor (as listed): Second Affiliated Hospital of Soochow UniversityPRaG 10.0NCT07267234
PRaG-1 Plus PRaG Therapy in Advanced Solid Tumors: A Prospective Clinical Trial (PRaG 10.0)
Investigates PRaG-1 cordycepin tablets added to a PRaG treatment program.
Not yet recruiting (registry record)
First posted: Dec 5, 2025 · Registry last updated: Dec 5, 2025Sponsor (as listed): Second Affiliated Hospital of Soochow UniversityNeoPRAGNCT06345599
PRaG Therapy in Combination With Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (NeoPRAG Study)
Evaluates a PRaG-based neoadjuvant strategy with chemotherapy in locally advanced pancreatic cancer.
Not yet recruiting (registry record)
First posted: Apr 3, 2024 · Registry last updated: Apr 3, 2024Sponsor (as listed): Second Affiliated Hospital of Soochow UniversityPRaG 9.0NCT06112041
The Prospective Clinical Study of Precision PRaG Therapy in Elderly Patients With Advanced Solid Malignant Tumors (PRaG9.0)
A prospective program focusing on older adults with advanced solid tumors.
Not yet recruiting (registry record)
First posted: Nov 1, 2023 · Registry last updated: Nov 1, 2023Sponsor (as listed): Second Affiliated Hospital of Soochow UniversityPRaG 2.0ENCT06047860
A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer
Explores recombinant human endostatin alongside PRaG in refractory lung cancer.
Status unknown / record not recently verified
First posted: Sep 21, 2023 · Registry last updated: Sep 21, 2023Sponsor (as listed): Second Affiliated Hospital of Soochow UniversityPRaG 5.0NCT05790447
Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors
Evaluates thymalfasin adjustment with a PRaG-based regimen.
Status unknown / record not recently verified
First posted: Mar 30, 2023 · Registry last updated: Mar 30, 2023Sponsor (as listed): Second Affiliated Hospital of Soochow UniversityPRaG 6.0NCT05603013
Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)
Examines metronomic vinorelbine added to radiotherapy, checkpoint inhibition and cytokines.
Status unknown / record not recently verified
First posted: Nov 2, 2022 · Registry last updated: Nov 2, 2022Sponsor (as listed): Second Affiliated Hospital of Soochow UniversityPRaG rechallengeNCT05530200
PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors.
Explores a PRaG-based approach after resistance to checkpoint inhibitors.
Status unknown / record not recently verified
First posted: Sep 7, 2022 · Registry last updated: Sep 7, 2022Sponsor (as listed): Second Affiliated Hospital of Soochow UniversityPRaG 4.0PNCT05501340
PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites
Investigates intraperitoneal PD-1 inhibitor delivery together with PRaG for malignant ascites.
Status unknown / record not recently verified
First posted: Aug 15, 2022 · Registry last updated: Aug 15, 2022Sponsor (as listed): Second Affiliated Hospital of Soochow UniversityPRaG + denosumabNCT05435768
PraG With RANKL Inhibitor for the Treatment of Advanced Multiple Metastatic Solid Tumors
Evaluates adding denosumab and different treatment sequences to a PRaG-based strategy.
Status unknown / record not recently verified
First posted: Jun 28, 2022 · Registry last updated: Aug 18, 2022Sponsor (as listed): Second Affiliated Hospital of Soochow UniversityPRaG 3.0NCT05115500
ADC Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of HER-2 Positive Advanced Solid Tumors(PRaG3.0)
Studies the combination of disitamab vedotin with a PRaG-based regimen in HER2-expressing tumors.
Status unknown / record not recently verified
First posted: Nov 10, 2021 · Registry last updated: Nov 10, 2021Sponsor (as listed): Second Affiliated Hospital of Soochow UniversityPRaG 2.0NCT04892498
Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)
Evaluates the addition of sequential IL-2 to a radiotherapy, checkpoint-inhibitor and GM-CSF regimen.
Status unknown / record not recently verified
First posted: May 19, 2021 · Registry last updated: Aug 9, 2022Sponsor (as listed): Second Affiliated Hospital of Soochow UniversitySWORDNCT04106180
SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC
An independent related trial for advanced non-small cell lung cancer; not a PRaG-series registration.
Status unknown / record not recently verified
First posted: Sep 26, 2019 · Registry last updated: Sep 26, 2019Sponsor (as listed): Fudan University